For example, treatment with Bevacizumab (an anti-angiogenic drug that targets VEGF-A), used to treat kidney, colon, rectum, lung, or breast tumors, and some brain tumors, causes a metabolic shift toward glycolysis making the remaining glioblastoma cell populations less dependent on angiogenesis and promoting the VCO typical pro-invasive phenotype in a subset of GBM patients (84, 85). This evidence concerns the gene VEGFA and glioblastoma.